INmune Bio’s (INMB) treatment of epidermolysis bullosa received FDA orphan designation, according to a post on the agency’s site.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio Announces Stock Options and Leadership Changes
- INmune Bio, OmniScience announce partnership to accelerate Alzheimer’s trial
- INmune Bio, OmniScience partner to accelerate trial with Vivo
- INmune Bio announces enrollment of 208 patients in Phase 2 trial of early AD
- Inmune Bio Emerges as Biotech Innovator in 2023